Palisade Bio (NASDAQ:PALI) is a biopharmaceutical company focused on developing innovative therapies that address unmet medical needs in the treatment of acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Their operations span through a wide range of activities, including drug development, clinical trials, and collaboration with healthcare professionals and researchers to bring new treatments to market. The company's flagship project involves the development of LB1148, a therapeutic that aims to accelerate the return of bowel function, reduce post-surgical adhesions, and potentially enhance the recovery of gastrointestinal surgery patients. With a mission rooted in improving patient outcomes and reducing healthcare costs, Palisade Bio is dedicated to pioneering novel healthcare solutions that can make a significant impact on patients' lives worldwide.